Researcher discovers metabolite of prostate cancer drug more effective at treating aggressive tumors

prostate cancer
Micrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer) Credit: Wikipedia

Cleveland: Cleveland Clinic researchers have discovered for the first time that a metabolite of an FDA-approved drug for metastatic prostate cancer, abiraterone (Abi), has more anti-cancer properties than its precursor. The research will be published online June 1st in Nature.

Cleveland Clinic researcher Nima Sharifi, M.D., found that abiraterone, a steroid inhibitor, is converted into the more physiologically active D4A (Δ4-abiraterone) in both and animal models with who take the drug. Furthermore, they found that D4A is more effective than abiraterone at killing aggressive prostate , suggesting that some patients may benefit from direct treatment with D4A.

Prostate cancer cells are fueled by androgens (male hormones). When prostate cancer spreads, androgen deprivation therapy ("medical castration") is used to cut off the tumor's energy supply. However, aggressive, metastatic tumors can become resistant to this type of therapy. In a landmark 2013 publication in Cell, Dr. Sharifi described a genetic mutation that enables to produce their own hormones for fuel, making them resistant to traditional hormone deprivation therapies.

Abiraterone works by blocking CYP17A1, an enzyme that is crucial for the production of androgens. Dr. Sharifi's team found that the more active D4A inhibits two additional enzymes responsible for producing androgens, as well as blocks the androgen receptor, which renders existing androgens inactive. They found that 12 patients on active abiraterone therapy had detectable serum levels of D4A. D4A levels varied among patients, however, suggesting that individuals may differ in their metabolism of abiraterone to D4A.

"More studies are needed to uncover the exact mechanisms involved, but we predict that direct treatment with D4A could prolong survival in some patients with ," said Dr. Sharifi, "Further studies will also help us develop a potential biomarker profile to predict which patients will respond to D4 - abiraterone."

Dr. Sharifi holds positions in Cleveland Clinic's Lerner Research Institute, Glickman Urological & Kidney Institute, and Taussig Cancer Institute, and is the Kendrick Family Endowed Chair for Prostate Cancer Research.

Prostate cancer is the most common cancer in men, with nearly 240,000 new cases diagnosed each year in the United State. According to the American Cancer Society, there will be an estimated 30,000 deaths due to prostate cancer in 2013. Almost every man who dies of prostate cancer dies with castration-resistant prostate cancer.


Explore further

Study finds genetic mutation in castration-resistant prostate cancer

More information: Conversion of abiraterone to D4A drives anti-tumor activity in prostate cancer, DOI: 10.1038/nature14406
Journal information: Cell , Nature

Provided by Cleveland Clinic
Citation: Researcher discovers metabolite of prostate cancer drug more effective at treating aggressive tumors (2015, June 1) retrieved 22 October 2019 from https://medicalxpress.com/news/2015-06-metabolite-prostate-cancer-drug-effective.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
30 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more